The existing majority shareholder of SHL Medical ("SHL") and EQT VIII Fund ("EQT") have entered into an agreement regarding the acquisition of a minority stake in SHL by EQT.
Headquartered in Switzerland, SHL is a world-leading provider of drug delivery solutions such as autoinjectors and serves as a partner to global pharmaceutical companies and biotech firms. The transaction is subject to customary regulatory approvals.
Milbank is advising the existing SHL majority shareholder on the transaction. The team is led by partner Steffen Oppenländer (Corporate/M&A, Munich) and includes partners Thomas Kleinheisterkamp (Tax, Munich) and Alexander Rinne (Regulatory, Munich) as well as associates Sebastian Dexheimer (Corporate/M&A, Frankfurt), Daniel Roggenkemper, Sebastian Reiner-Pechtl (both Corporate/M&A, Munich), Stefan Kreuzer (Tax, Munich) and Nils Bremer (Regulatory, Munich).